Ngomhla we-5 kaJulayi, uNovo Nordisk uqalise ulingo lwekliniki lwesigaba III se-CagriSema injection e-China, injongo yayo kukuthelekisa ukhuseleko kunye nokusebenza kakuhle kwe-CagriSema injection kunye ne-semeglutide kwizigulane ezigqithiseleyo kunye ne-overweight e-China.
I-injection ye-CagriSema yonyango oludibeneyo olusebenza ixesha elide phantsi kophuhliso lwe-Novo Nordisk, amacandelo aphambili yi-GLP-1 (i-glucagon-like peptide-1) i-receptor agonist smeglutide kunye ne-amylin analog cagrilintide yexesha elide.Inaliti yeCagriSema inokufakwa ngaphantsi kwesikhumba kanye ngeveki.
Injongo ephambili yayikuthelekisa iCagriSema (2.4 mg / 2.4 mg) kunye ne-semeglutide okanye i-placebo kanye ngeveki ngaphantsi kwe-subcutaneously.I-Novo Nordisk ibhengeze iziphumo zovavanyo lwe-CagriSema kunyango lwe-2 yesifo sikashukela, ebonise ukuba i-CagriSema i-hypoglycemic effect ingcono kune-semeglutide, kwaye phantse i-90% yezifundo ziye zafikelela injongo ye-HbA1c.
Idatha ibonise ukuba ngaphezu kwempembelelo ebalulekileyo ye-hypoglycemic, malunga nokulahlekelwa kwesisindo, i-CagriSema injection iphumelele kakhulu i-semeglutide (5.1%) kunye ne-cagrilintide (8.1%) kunye nokulahlekelwa kwesisindo se-15.6%.
Ichiza elivelisa izinto ezintsha iTirzepatide lelokuqala elivunyiweyo leveki yonke leGIP/GLP-1 receptor agonist.Idibanisa imiphumo yee-incretins ezimbini kwi-molecule enye ejojowe kanye ngeveki kwaye iklasi entsha yonyango lwe-2 yeswekile.I-Tirzepatide ivunyiwe yi-US Food and Drug Administration (FDA) ngoMeyi 2022 ukuphucula ulawulo lwe-glycemic (kwisiseko sokutya kunye nokuzivocavoca) kubantu abadala abanesifo sikashukela sohlobo lwe-2 kwaye okwangoku kuvunyiwe kwi-European Union, eJapan nakwamanye amazwe.
Ngomhla we-5 kaJulayi, u-Eli Lilly ubhengeze isifundo se-III SURPASS-CN-MONO malunga nokubhaliswa kovavanyo lweklinikhi yeziyobisi kunye neqonga lokudiza ulwazi lonyango lwezigulane ze-2 zeswekile.I-SURPASS-CN-MONO i-randomized, i-double-blind-blind, i-placebo-controlled phase III isifundo eyenzelwe ukuvavanya ukusebenza kunye nokhuseleko lwe-tirzepatide monotherapy xa kuthelekiswa ne-placebo kubantu abanesifo sikashukela sohlobo lwe-2.Uphononongo lucebe ukubandakanya izigulane ezingama-200 ezinesifo sikashukela sohlobo lwe-2 ezazingekho kuzo naziphi na izidakamizwa ze-antidiabetic kwiintsuku ze-90 ngaphambi kokutyelela i-1 (ngaphandle kweemeko ezithile zeklinikhi, ezifana nokugula okunzima, ukulaliswa esibhedlele, okanye utyando olukhethiweyo, ixesha elifutshane (≤14 iintsuku) ukusetyenziswa kwe-insulin).
Uhlobo lwe-2 yeswekile kulindeleke ukuba luvunywe kulo nyaka
Kwinyanga ephelileyo, iziphumo zesifundo se-SURPASS-AP-Combo zapapashwa ngoMeyi 25 kwijenali blockbuster Nature Medicine.Iziphumo zibonise ukuba xa kuthelekiswa ne-insulin glargine, i-Tirzepatide ibonise i-HbA1c engcono kunye nokunciphisa ubunzima kuluntu lwe-2 yesifo sikashukela kwingingqi ye-Asia-Pacific (ikakhulukazi i-China): ukunciphisa i-HbA1c ukuya kwi-2.49% kunye nokunciphisa ubunzima ukuya kwi-7.2 kg. (9.4%) kwiiveki ze-40 zonyango, ukuphuculwa okuphawulekayo kwi-lipids yegazi kunye noxinzelelo lwegazi, kunye nokhuseleko jikelele kunye nokunyamezela kwakukuhle.
ISigaba sesi-3 solingo lwezonyango lwe-SURPASS-AP-Combo luphononongo lokuqala lwe-Tirzepatide oluqhutywe ikakhulu kwizigulane zaseTshayina ezinesifo seswekile esi-2, ekhokelwa nguNjingalwazi uJi Linong weSibhedlele saBantu seYunivesithi yasePeking.I-SURPASS-AP-Combo iyahambelana neziphumo zochungechunge lwehlabathi lwe-SURPASS lophando, olungqina ngakumbi ukuba i-pathophysiology yesifo seswekile kwizigulana zaseTshayina iyahambelana nezigulane zehlabathi, ezisisiseko sophando kunye nophuhliso lwamachiza amatsha. e-China kunye nehlabathi, kwaye ikwabonelela ngenkxaso yobungqina obuqinileyo bokunika izigulane zaseTshayina ithuba lokusebenzisa amayeza onyango lweswekile yamva nje kunye nesicelo sabo seklinikhi eTshayina ngokukhawuleza.
Ixesha lokuposa: Sep-18-2023